Heart failure & cardiomyopathiesGuideline or statement
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association
- Clinical consensus statement
Recommendations
As issued by the authors
TAVR as the preferred treatment for AS in patients with ATTR-CM
Original publication
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J. Published 7 October 2025. doi:10.1093/eurheartj/ehaf710
Summarised from the published abstract; every number is checked against it